Cargando…

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice

Background The anti-programmed cell death one antibodies (Anti-PD-1 Ab) pembrolizumab or nivolumab are commonly prescribed to patients with advanced melanoma. The purpose of the current study is to identify baseline clinical characteristics associated with time to treatment initiation (TTI) of pembr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ksienski, Doran, Truong, Pauline T, Croteau, Nicole S, Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Lesperance, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702391/ https://www.ncbi.nlm.nih.gov/pubmed/34963849 http://dx.doi.org/10.7759/cureus.19835

Ejemplares similares

Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic
por: Ksienski, Doran, et al.
Publicado: (2022)

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
por: Ksienski, Doran, et al.
Publicado: (2021)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
por: Oprea, Adela-Raluca, et al.
Publicado: (2022)

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
por: Lakkunarajah, Suganija, et al.
Publicado: (2023)

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab
por: Singh, Arminder, et al.
Publicado: (2021)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023)

Recurrent Erythema Multiforme Induced by the Combination of Pembrolizumab and Radiation
por: Ambur, Austin B, et al.
Publicado: (2021)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

A Case of Bullous Pemphigoid Associated With Nivolumab Therapy
por: Gotera, Nico, et al.
Publicado: (2022)

Pembrolizumab-Induced Lichenoid Dermatitis in a Patient With Metastatic Cancer of Unknown Primary
por: Sethi, Ashish, et al.
Publicado: (2021)

Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature
por: Thomas, Mathew, et al.
Publicado: (2022)

Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient
por: Tembunde, Yazmeen, et al.
Publicado: (2023)

Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
por: Cristancho, Cagney, et al.
Publicado: (2020)

Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
por: Wilkins, Matthew C, et al.
Publicado: (2021)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Nivolumab-Induced Toxic Epidermal Necrolysis: Rare but Fatal Complication of Immune Checkpoint Inhibitor Therapy
por: Kim, Michael C, et al.
Publicado: (2021)

Photosensitive rash induced by nivolumab()
por: Navarro-Triviño, Francisco J., et al.
Publicado: (2022)

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report
por: Chatterjee, Tulika, et al.
Publicado: (2022)

Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response
por: Sehbai, Aasim, et al.
Publicado: (2022)

Non-Melanoma-Associated Dyschromia of the Proximal Nail Fold
por: DeMartinis, Nicole C, et al.
Publicado: (2016)

Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma
por: Asemota, Uyioghosa, et al.
Publicado: (2021)

Pembrolizumab-induced rash in a patient with angiosarcoma
por: Qian, Justin, et al.
Publicado: (2022)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report
por: Sandhu, Michael, et al.
Publicado: (2023)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
por: Ebia, Matthew I, et al.
Publicado: (2021)

Primary Left Thigh Melanoma Presenting as an Obstructive Hemorrhagic Melanoma of the Small Bowel
por: Galindo, Lidice, et al.
Publicado: (2023)

Aggressive Nodular Malignant Melanoma
por: Myers, Daniel J, et al.
Publicado: (2021)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

Subungual Amelanotic Melanoma Masquerading as Onychomycosis
por: Riahi, Ryan R, et al.
Publicado: (2018)

Primary Malignant Melanoma of the Urinary Bladder
por: Snajdar, Elizabeth, et al.
Publicado: (2021)

Melanoma Extension for Community Healthcare Outcomes: A Feasibility Study of Melanoma Screening Implementation in Primary Care Settings
por: Becevic, Mirna, et al.
Publicado: (2021)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
por: Ksienski, Doran
Publicado: (2011)

Recognizing Histopathological Simulators of Melanoma to Avoid Misdiagnosis
por: Waqar, Sara, et al.
Publicado: (2022)

Amelanotic Malignant Melanoma: A Case Report
por: Karmilkar, Kunal, et al.
Publicado: (2023)

A Rare Case of Acral Lentiginous Melanoma
por: Meghe, Soham, et al.
Publicado: (2023)

Point prevalence of non-melanoma and melanoma skin cancers in Australian surfers and swimmers in Southeast Queensland and Northern New South Wales
por: Climstein, Mike, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3hnmpl0be9t29d5k5fh9td5um